close

Clinical Trials

1 2 3 206
Number of results: 4110

Excel print is not allowed for data more than 300.Please search above for fewer data.

Date Product Disease Phase Company Therapeutic area
2017-12-12 UCART19 relapsed or refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) 1 Cellectis (France) Servier (France) Pfizer (USA - NY) Cancer - Oncology
2017-12-12 UCART19 relapsed/refractory B acute lymphoblastic leukaemia (ALL) 1 Cellectis (France) Servier (France) Pfizer (USA - NY) Cancer - Oncology
2017-12-11 crizanlizumab (SEG101) sickle cell disease 2 Novartis (Switzerland) Cancer - Oncology
2017-12-11 LentiGlobin® BB305 (autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) beta-thalassemia, sickle cell disease 1-2 bluebird bio (USA - MA) Hematologic diseases - Genetic diseases - Rare diseases
2017-12-11 CAEL-101 (mAb 11-1F4) amyloid light chain amyloidosis 1b Caelum Biosciences (USA - NY) Rare diseases - Genetic diseases
2017-12-10 polatuzumab vedotin people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for hematopoietic stem cell transplant. 1b-2 Roche (Switzerland) Cancer - Oncology
2017-12-10 Adcetris® (brentuximab vedotin) Hodgkin lymphoma 3 Seattle Genetics (USA - WA) Cancer - Oncology
2017-12-10 Elocta™/Eloctate™ (recombinant factor VIII Fc fusion protein - rFVIIIFc) hemophilia A 3 BiogenIdec (USA) Swedish Orphan Biovitrum SOBI (Sweden) Hematologic diseases - Genetic diseases
2017-12-09 Sprycel® (dasatinib) newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) 2 BMS (USA - NY) Cancer - Oncology
2017-12-09 chimeric antigen receptor (CAR)-targeted CD8alphabeta+ T cells preclinical Fate Therapeutics (USA - CA) Cancer - Oncology
2017-12-09 Adcetris® (brentuximab vedotin) CD30-expressing cutaneous T-cell lymphoma (CTCL) 3 Millenium Pharmaceuticals (USA - MA) Seattle Genetics (USA - WA), wholly owned subsidiaries of Takeda Pharmaceutical (Japan) Cancer - Oncology
2017-12-09 IMGN779 acute myeloid leukemia, refractory acute myeloid leukemia 1 immunogen (USA - MA) Cancer - Oncology
2017-12-09 emicizumab (ACE910 - anti-factor IXa x anti-factor X humanized bispecific antibody) hemophilia A 3 Roche (Switzerland) Rare diseases - Genetic diseases - Hematological diseases
2017-12-09 emicizumab (ACE910 - anti-factor IXa x anti-factor X humanized bispecific antibody) hemophilia A 3 Roche (Switzerland) Rare diseases - Genetic diseases - Hematological diseases
2017-12-09 BMN 270 - valoctocogene roxaparvovec- adeno-associated viral vector serotype 5 containing a B-domain deleted variant of human coagulation factor VIII gene hemophilia A 1-2 Biomarin Pharmaceutical (USA - CA) Rare diseases - Genetic diseases - Hematological diseases
2017-12-09 AMT-061 severe and moderately severe hemophilia B preclinical Uniqure (The Netherlands) Rare diseases - Genetic diseases - Hematological diseases
2017-12-07 emicizumab (ACE910 - anti-factor IXa x anti-factor X humanized bispecific antibody) hemophilia A 3 Roche (Switzerland) Rare diseases - Genetic diseases - Hematological diseases
2017-12-07 Tedopi® (OSE2101) non-­small cell lung cancer 3 OSE Pharma (France) now OSE Immunotherapeutics Cancer - Oncology
2017-12-06 SPK-8011 hemophilia A 1-2 Spark Therapeutics (USA - PA) Rare diseases - Genetic diseases - Hematological diseases
2017-12-05 MNK1 and MNK2 (MNK1/2) kinase inhibitor discovery program preclinical Oncodesign (France)